

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

UPDATED INFORMATION OF THE GROUP'S PRODUCT

This announcement is made by The United Laboratories International Holdings Limited (the "Company") on a voluntary basis.

The board of directors (the "Board") of the Company is pleased to announce that sodium hyaluronate eye drops (Specification: 0.1% (0.4ml: 0.4mg)) applied by Zhuhai United Laboratories Co., Ltd., Zhongshan Branch, a wholly-owned subsidiary of the Company, has been approved for marketing by China National Medical Products Administration, and is deemed to have passed the consistency evaluation of quality and efficacy for generic drugs (the "Consistency Evaluation").

Sodium hyaluronate eye drops are indicated for xerophthalmia and it can relieve dry eye symptoms. Except for the specification difference from the marketed sodium hyaluronate eye drops (Specification: 5ml: 5mg; 7ml: 7mg) of the Company, this approved product is an OTC drug and is packaged in single dose (i.e. disposable eye drops) without preservatives, which is non-cross-infectious, portable and economical.

The approval further enriches the Company's ophthalmic product pipeline and helps to enhance the Company's market competitiveness in the field of drugs for the treatment of xerophthalmia. The Company will continue to focus on the research and development of new products and the promotion of the Consistency Evaluation, which is expected to create greater benefits for the Company and its shareholders.

By Order of the Board

The United Laboratories International Holdings Limited

Tsoi Hoi Shan

Chairman

Hong Kong, 14 October 2022

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.